Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) FCF Margin: 2011-2025

Historic FCF Margin for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to 10.79%.

  • Niagen Bioscience's FCF Margin fell 271.00% to 10.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.96%, marking a year-over-year increase of 1253.00%. This contributed to the annual value of 11.99% for FY2024, which is 366.00% up from last year.
  • Per Niagen Bioscience's latest filing, its FCF Margin stood at 10.79% for Q3 2025, which was up 205.86% from 3.53% recorded in Q2 2025.
  • Niagen Bioscience's FCF Margin's 5-year high stood at 29.23% during Q4 2024, with a 5-year trough of -46.10% in Q2 2021.
  • Its 3-year average for FCF Margin is 10.52%, with a median of 10.79% in 2025.
  • In the last 5 years, Niagen Bioscience's FCF Margin crashed by 3,672bps in 2021 and then soared by 5,383bps in 2023.
  • Quarterly analysis of 5 years shows Niagen Bioscience's FCF Margin stood at -27.85% in 2021, then surged by 2,547bps to -2.38% in 2022, then soared by 534bps to 2.96% in 2023, then spiked by 2,627bps to 29.23% in 2024, then tumbled by 271bps to 10.79% in 2025.
  • Its FCF Margin was 10.79% in Q3 2025, compared to 3.53% in Q2 2025 and 25.81% in Q1 2025.